News about Clinical Trials

Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025

Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.

Clinical Trials | 01/09/2026 | By News Bureau

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110 HER2 ADC Biosimilar

Formosa Pharmaceuticals files a clinical trial application for TSY-110, a HER2-targeting Antibody Drug Conjugate (ADC) biosimilar positioned as a potential alternative to Roche’s Kadcyla.

Clinical Trials | 01/09/2026 | By News Bureau

Ireland Establishes Clinical Trials Advisory Council to Accelerate Clinical Research Reforms

Ireland’s new Clinical Trials Advisory Council held its inaugural meeting on August 27, 2026, beginning work on reforms aimed at improving clinical research, patient access and life sciences investment.

Clinical Trials | 31/08/2026 | By News Bureau

Zydus Reports Positive Phase 2b Results for Saroglitazar in MASH

Zydus reports positive phase 2b EVIDENCES-X results for saroglitazar magnesium in MASH, meeting its primary endpoint of steatohepatitis resolution without worsening fibrosis.

Clinical Trials | 31/08/2026 | By News Bureau

Daiichi Sankyo and AstraZeneca Dose First Patient in Phase 3 Trial of Datroway for Muscle-Invasive Urothelial Cancer

The first patient has been dosed in the global Phase 3 TROPION-Urothelial04 trial, advancing evaluation of Datroway-based therapies for high-risk muscle-invasive urothelial cancer.

Clinical Trials | 27/08/2026 | By News Bureau

Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval

Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.

Clinical Trials | 26/08/2026 | By News Bureau

Astellas Doses First Patient in Phase 3 ASP2138 Study for Gastric Cancer

Astellas doses the first patient in its phase 3 ASP2138 study for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction cancer.

Clinical Trials | 26/08/2026 | By News Bureau

Milestone Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Etripamil for AFib-RVR

Milestone Pharmaceuticals has begun its Phase 3 ReVeRA-301 trial to evaluate self-administered etripamil nasal spray for acute AFib-RVR, targeting rapid ventricular rate reduction and symptom relief.

Clinical Trials | 24/08/2026 | By News Bureau

Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China

Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.

Clinical Trials | 24/08/2026 | By News Bureau

OncoC4 Doses First Patient in Phase 1 Trial of ONC-783 T-Cell Engager

OncoC4 has dosed the first patient in its Phase 1 ONC-783-001 trial, evaluating the investigational T-cell engager ONC-783, developed to target the cancer-specific neoCD24 epitope in patients with advanced solid tumours.

Clinical Trials | 18/08/2026 | By News Bureau